The Patent Finder

1- [2- (2,4-Dimethylphenylsulfanyl)-PHENYL] Piperazine as a Compound with Combined Serotonin Reuptake, 5-HT3 and 5-HT1A Activity for the Treatment of Cognitive Impairment

H. Lundbeck A/S

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 10 of these applications claim priority to application PCT/DK2007/050075, filed Jun 15, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 8,969,3551-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · High confidence
UsedRemaining
H. Lundbeck A/SIn forceHigh confidence
US 9,095,588Process for Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-PHENY]PIPERAZINE or Pharmaceutically Acceptable Salt Thereof
In force
 · Medium confidence
H. Lundbeck A/SIn forceMedium confidence
US 9,101,626Process For Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine Or Pharmaceutically Acceptable Salt Thereof
In force
 · High confidence
H. Lundbeck A/SIn forceHigh confidence
US 9,125,9081-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · High confidence
H. Lundbeck A/SIn forceHigh confidence
US 9,125,9091-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · Medium confidence
H. Lundbeck A/SIn forceMedium confidence
US 9,125,9101-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · Medium confidence
H. Lundbeck A/SIn forceMedium confidence
US 9,227,9461-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · High confidence
H. Lundbeck A/SIn forceHigh confidence
US 9,861,6301-[2-(2,4-Dimethylphenylsulfanyl)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
In force
 · High confidence
H. Lundbeck A/SIn forceHigh confidence
US 11,458,1341-[2-(2,4-Dimethylphenylsulfanyl)-PHENYL]PIPERAZINE as a Compound with Combined Serotonin Reuptake, 5-HT3 and 5-HT1A Activity for the Treatment of Cognitive Impairment
In force
 · High confidence
H. Lundbeck A/SIn forceHigh confidence
US 8,722,6841- [2- (2,4-Dimethylphenylsulfanyl)-PHENYL] Piperazine as a Compound with Combined Serotonin Reuptake, 5-HT3 and 5-HT1A Activity for the Treatment of Cognitive Impairment
In force
 · High confidence
H. Lundbeck A/SIn forceHigh confidence
3 more records in this group · Pro
10 of 13 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 13, including 9 expiring within the 18 months from Nov 19, 2026.
Upgrade to Pro
10 of these are in force and held by H. Lundbeck A/S.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited